CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...
Phase 3
Valencia, Spain and 295 other locations
compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effec...
Phase 2
Valencia, Spain and 93 other locations
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney...
Phase 2
Valencia, Spain and 112 other locations
Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial ...
Phase 3
Valencia, Spain and 338 other locations
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys...
Phase 2
Valencia, Spain and 168 other locations
and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...
Phase 3
Valencia, Spain and 642 other locations
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2...
Phase 2
Valencia, Spain and 122 other locations
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...
Phase 3
Valencia, Spain and 208 other locations
(for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.Parti...
Phase 3
Valencia, Spain and 850 other locations
of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/ ...
Phase 3
Valencia, València, Spain and 825 other locations
Clinical trials
Research sites
Resources
Legal